PDCD1 and glioblastoma: In mice bearing anti-PD1-resistant glioblastoma, the CCR2 antagonist CCX872 enhanced the efficacy of anti-PD1 via a reduction in MDSCs and a concomitant increase in functional T cells within the tumours, significantly improving the overall survival of mice [73].